Is Scoop profitable in 2026?

No. Scoop is a pre-seed, roughly 2-person Y Combinator Fall 2025 startup with no disclosed revenue, ARR, or named customers as of mid-2026; its Launch YC page (2025-11-09) describes the problem it targets but cites no paying clients.

Could AI replace what Scoop is building?

The workflow itself (turning biotech data into IND regulatory documents) is broadly seen as AI-automatable, since at least five other AI-native startups, including Weave Bio, Ritivel, Raycaster and Artos, are attacking the identical task as of mid-2026.

Who is Scoop's biggest competitor?

Weave Bio, founded 2022, is Scoop's most advanced rival: it has a live eCTD Submission Builder product, a $10M seed from May 2024, roughly $36M raised total, and a named CRO design partnership with Parexel disclosed by 2025-10-22.

Scoop is privately held, founded in 2025 by CTO 'Jay' (ex-Google Search applied AI, prior IND-filing experience at Genentech/Corestem) and CEO Vincent Park (ex-Persona, ex-Dropbox), and is backed by Y Combinator's Fall 2025 batch.

Has Scoop raised a seed round?

No independent seed round, valuation, or named investors beyond Y Combinator's standard batch investment have been publicly disclosed for Scoop as of 2026-07-16.

What does Scoop actually build?

Scoop builds AI agents that ingest a biotech's internal study and manufacturing data and turn it into ready-to-submit, continuously updated regulatory documents, starting with IND filings for first-in-human drug trials, per its 2025-11-09 Launch YC announcement.

YC Fall 2025 · United States

Scoop

YC-backed startup building AI agents to automate IND regulatory filings for biotech.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Window to land a named CRO or biotech pilot and publish an FDA-cleared IND case study

The call

Scoop is chasing an open but narrowing window in IND automation while a funded AI-native rival and Veeva both already move on the same ground.

Scoop helps pharmaceutical companies handle the huge amount of paperwork required for clinical trials, which is currently done mostly by hand. The company is racing against Weave Bio, which already has partnerships with major trial companies and FDA approval proof, plus Veeva Systems, the giant software company that runs trial data and just bought another automation company. Without announcing a real partnership with a major clinical research company or trial organization by mid-2026, Scoop will likely lose to rivals that have more trust signals, deeper pockets, and better connections to the pharmaceutical industry. The one thing that could flip the situation is if Scoop lands a named partnership or pilot customer announcement that proves it can handle the liability concerns that matter most in this industry.

Why

AI pressure: Weave Bio's AutoIND / eCTD Submission Builder. Weave Bio already runs a live AI tool for IND modules 1,2,3,5 with a named CRO partner, the exact ground Scoop wants to take. Could AI do the core job? Yes, likely.

Bigger players: Veeva Systems. Veeva bought Ostro in March 2026 and could bolt IND-authoring AI onto Vault, the system biotechs already run on. Could a giant copy it? Yes, easily.

What protects it. Founders' biotech and AI pedigree (Genentech, Google Gemini, Persona) if they turn it into a named pilot fast.

What would change this call

Scoop announces its first named pilot customer or CRO partnership within the next two quarters. Would show Scoop finally building the trust/liability seal it currently lacks.
Veeva announces an IND-authoring agent launch or acquires an IND-automation startup. Would show the system-of-record incumbent closing the gap Scoop is racing to fill.
Weave Bio announces a Series B round or acquisition offer. Would show Weave Bio consolidating its lead before Scoop gains named traction.

Key numbers

Weave Bio raised ~$36M total incl. $20M Series A (2026-07-16)
Weave Bio has CRO design partnership with Parexel (2025-10-22)
Scoop launched via YC Fall 2025 batch (2025-11-09)

Named risks

No disclosed funding, revenue, or customers as of mid-2026 while rivals are better capitalized. Severity: high
Weave Bio already holds the CRO trust signal (Parexel partnership, FDA case study) Scoop lacks. Severity: high
Veeva, the entrenched Vault incumbent, faces no structural barrier to building or acquiring this capability. Severity: high
At least five to six similarly staged AI-native startups target the identical IND automation workflow. Severity: medium
Liability-sensitive regulatory vertical requires trust signals Scoop has not yet demonstrated. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Weave Bio	losing to	Weave Bio has live product, $36M raised, and named Parexel CRO partnership as of 2025-10-22; Scoop has none disclosed
Veeva Systems	losing to	Veeva bought AI-agent firm Ostro for ~$100M in March 2026, moving into the space Scoop targets
Ritivel	contesting	Ritivel launched on YC 2026-01-30 with similar AI-native IND/CTD drafting workspace
Artos	contesting	YC-backed Artos launched 2024-01-29 targeting the same regulatory submission drafting task
Raycaster	contesting	Raycaster positions as 'Cursor/Devin for life sciences documents,' covering the same regulatory workflow

Questions people ask

Is Scoop profitable in 2026?: No. Scoop is a pre-seed, roughly 2-person Y Combinator Fall 2025 startup with no disclosed revenue, ARR, or named customers as of mid-2026; its Launch YC page (2025-11-09) describes the problem it targets but cites no paying clients.
Could AI replace what Scoop is building?: The workflow itself (turning biotech data into IND regulatory documents) is broadly seen as AI-automatable, since at least five other AI-native startups, including Weave Bio, Ritivel, Raycaster and Artos, are attacking the identical task as of mid-2026.
Who is Scoop's biggest competitor?: Weave Bio, founded 2022, is Scoop's most advanced rival: it has a live eCTD Submission Builder product, a $10M seed from May 2024, roughly $36M raised total, and a named CRO design partnership with Parexel disclosed by 2025-10-22.
Who owns Scoop?: Scoop is privately held, founded in 2025 by CTO 'Jay' (ex-Google Search applied AI, prior IND-filing experience at Genentech/Corestem) and CEO Vincent Park (ex-Persona, ex-Dropbox), and is backed by Y Combinator's Fall 2025 batch.
Has Scoop raised a seed round?: No independent seed round, valuation, or named investors beyond Y Combinator's standard batch investment have been publicly disclosed for Scoop as of 2026-07-16.
What does Scoop actually build?: Scoop builds AI agents that ingest a biotech's internal study and manufacturing data and turn it into ready-to-submit, continuously updated regulatory documents, starting with IND filings for first-in-human drug trials, per its 2025-11-09 Launch YC announcement.

Timeline

2026-04-12Aggregator lists Scoop at roughly 2-person team, San Francisco, 2025 active
2026-03Veeva Systems announces ~$100M acquisition of AI-agent company Ostro
2026-01-30Rival Ritivel launches on YC with AI-native regulatory document workspace
2025-12EU pharma law reform takes effect, potentially shifting submission format rules
2025-11-09Scoop publicly launches via Y Combinator Launch YC post
2025-10-22Weave Bio's Parexel CRO partnership and eCTD product publicly detailed
2024-05Weave Bio raises $10M seed co-led by Innovation Endeavors and Magnetic Ventures
2024-01-29Rival Artos launches on YC targeting regulatory submission drafting

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Nexus Terrain Metorial